Connect with us

Press Release

CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

Published

4 months ago

on

SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, “MG-K10” or the “Product”), a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026. The Product is proposed for the treatment of adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms remain inadequately controlled after treatment with intranasal corticosteroids.

The acceptance of the NDA represents an important milestone for the Group’s ophthalmology business, CMS Vision, as it expands its therapeutic focus from ophthalmology into the field of otolaryngology (ENT). It also marks another significant milestone in the Group’s research and development progress in the field of type 2 inflammatory diseases. If the Product is successfully approved for marketing, the Group will leverage its strong academic promotion capabilities and extensive commercialization network to accelerate the commercialization of the Product. It is also expected to further enhance the academic brand influence of CMS Vision in the relevant specialty areas and provide new momentum for the Group’s business growth.

BIC Potential: Dosing once every 4 weeks; Phase III study met the primary endpoint with a favorable safety profile

MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling pathways of the key type 2 inflammatory cytokines IL-4 and IL-13, thereby exerting immunomodulatory effects. It is being developed for the treatment of type 2 inflammatory diseases, including seasonal allergic rhinitis, asthma, atopic dermatitis (AD), prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Currently marketed anti-IL-4Rα therapies require administration once every two weeks. MG-K10, with its longer half-life, enabling a once-every-four-weeks dosing regimen. It therefore has the potential to become the first long-acting anti-IL-4Rα monoclonal antibody to be marketed globally, with the potential to be best-in-class. MG-K10 has met the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial in adult patients with moderate-to-severe seasonal allergic rhinitis. The results of the Phase III study demonstrated that the primary endpoint achieved statistical significance, with significantly superior efficacy compared with the placebo group, and a favorable safety profile.

Focusing on Unmet Needs: ~250 million patients; 62% of moderate-to-severe patients remain inadequately controlled; long-acting breakthrough brings new treatment opportunities

Allergic rhinitis is a chronic inflammatory disease of the nasal mucosa mediated by IgE, with type 2 inflammation as the core pathogenic mechanism. It occurs in susceptible individuals upon exposure to environmental allergens such as pollen and dust mites. In recent years, the prevalence of the disease in China has increased from 11.1% to 17.6%, affecting approximately 250 million people[1], among whom 52.2% are patients with persistent moderate-to-severe disease[2]. The disease burden is significant and has become an important public health issue. Current standard treatments, including intranasal corticosteroids and antihistamines, have notable limitations. 62% of patients with moderate-to-severe disease remain inadequately controlled[3]. Long-term use of intranasal corticosteroids may lead to adverse reactions such as epistaxis[4], while antihistamines are often associated with side effects such as drowsiness[5], indicating significant unmet clinical needs. As a biologic therapy targeting IL-4Rα, MG-K10 can block the type 2 inflammatory pathway at its source. Compared with currently approved biologics targeting the same pathway (which require dosing once every two weeks), MG-K10 achieves a differentiated breakthrough in dosing frequency with its long-acting property allowing administration once every four weeks, thereby significantly extending dosing intervals. This may help improve patient treatment adherence and reduce the time and economic burden associated with frequent hospital visits. The Product has the potential to provide a new treatment option for patients with moderate-to-severe disease who respond poorly to conventional therapies, thereby reducing the individual and socio-economic burden associated with the disease.

On 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiary for MG-K10. In accordance with the Agreement and supplementary agreements, the Group has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon Holdings Limited has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference

  1. Cheng L, Chen J, Fu Q, et al. Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2018;10:300‑353.
  2. Zheng, Ming et al. “Clinical characteristics of allergic rhinitis patients in 13 metropolitan cities of China.” Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.14561
  3. White, P et al. “Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x
  4. Rosenblut, A et al. “Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.” Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x
  5. Bernstein, Jonathan A et al. “Allergic Rhinitis: A Review.” JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations 

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Kara4Kids Expands Early Childhood Education Across India With Inclusive, Play-Based Learning

Published

46 minutes ago

on

August 15, 2026

By

India, 15th Aug 2026 — Kara4Kids, an early childhood education and childcare provider with more than 18 years of experience, is strengthening its presence across India with preschool, daycare and early learning programs designed to support children during their formative years. With more than eight locations across Bengaluru, Chennai and Hyderabad, Kara4Kids offers families a range of programs focused on learning, development, safety and inclusive care.

The organization currently has admissions open for the 2026–27 academic year, providing families with access to preschool and childcare programs for young children. Its preschool programs generally serve children approximately 2 to 6 years of age, while infant and toddler care and other childcare options are also available.

At the center of Kara4Kids’ educational philosophy is an approach that combines play-based, inquiry-based and project-based learning. Rather than relying solely on conventional classroom instruction, the learning environment encourages children to explore ideas, ask questions, participate in activities and develop skills through age-appropriate experiences.

Kara4Kids incorporates a STREAM approach, together with Developmentally Appropriate Practices (DAP), to create learning experiences aligned with children’s developmental stages. The approach supports multiple areas of childhood development, including cognitive, language, physical, social and emotional growth.

The programs are designed to provide children with opportunities to build communication skills, develop curiosity, interact with peers and gain greater independence in an environment structured around their developmental needs. Activities and learning experiences are adapted to encourage participation and discovery while helping children establish foundational skills for their next stages of education.

A key aspect of Kara4Kids’ model is its emphasis on inclusive early childhood education. The organization provides an environment that accommodates children with different learning and developmental needs, including special-needs care. This focus on inclusion aims to create learning spaces where children can participate, interact and develop alongside their peers while receiving appropriate support.

Beyond classroom learning, Kara4Kids places importance on maintaining an active connection between educators and families. Parent-teacher workshops, progress updates, family events and guidance for learning at home are part of its parent involvement initiatives. By encouraging communication between parents and educators, the organization seeks to provide families with a clearer understanding of children’s progress and ways to support continued learning beyond the classroom.

Safety and wellbeing are also central to the Kara4Kids experience. Its childcare and preschool environments are designed around child-safe campuses, hygiene protocols and health monitoring practices. Low teacher-student ratios are intended to support attentive supervision and enable educators to respond more closely to children’s individual needs.

The organization’s work in early education has also received recognition from several education-focused organizations and platforms, including EducationWorld, Education Today, Times Education Excellence, ScooNews/Global Education Awards and the India Didactics Association.

More recently, Kara4Kids received a Certificate of Excellence for Innovation in Early Childhood Development at the Global Education Awards 2026. The recognition reflects the organization’s continued focus on developing approaches to early learning that combine educational innovation with children’s developmental needs.

With its expanding presence across Bengaluru, Chennai and Hyderabad, Kara4Kids continues to provide families with preschool, daycare and childcare options under one educational framework. Its offerings include preschool education, daycare, infant and toddler care, after-school care, emergency daycare and inclusive care for children with special needs.

As families consider educational and childcare options for the coming academic year, Kara4Kids is currently welcoming admissions for 2026–27. The organization remains focused on creating early learning environments where children can explore, develop essential skills and build positive foundations for lifelong learning.

For more information visit https://kara.in/ .

About Kara4Kids

Kara4Kids is an early childhood education, preschool, daycare and childcare provider with more than 18 years of experience in early education. With over eight locations across Bengaluru, Chennai and Hyderabad, the organization provides preschool, infant and toddler care, daycare, after-school care, emergency daycare and inclusive special-needs care. Its educational approach combines play-based, inquiry-based and project-based learning with STREAM and Developmentally Appropriate Practices.

Media Contact

Organization: Kara4Kids

Contact Person: Kara4Kids

Website: https://kara.in/

Email: Send Email

Country:India

Release id:48132

The post Kara4Kids Expands Early Childhood Education Across India With Inclusive, Play-Based Learning appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ROYAL PARKS AKABANE NORTH Highlights Convenient Rental Living in Tokyo

Published

46 minutes ago

on

August 15, 2026

By

Japan, 15th Aug 2026 — ROYAL PARKS AKABANE NORTH is drawing attention within Tokyo’s residential market as a rental property option for individuals seeking comfortable and convenient urban living. Located in the Akabane area of Tokyo, the property offers residents an opportunity to enjoy the advantages of a well-connected neighborhood while remaining within reach of the city’s major commercial and lifestyle destinations.

Tokyo continues to attract professionals, students, families, and people relocating for business and personal opportunities. As demand for quality housing remains strong, ROYAL PARKS AKABANE NORTH Rental Apartments provide an option for those looking to establish a home in a convenient part of the metropolitan area.

Akabane is known for its transportation accessibility and diverse selection of shopping, dining, and everyday services. The area’s connections make it practical for residents who need to travel to different parts of Tokyo while also providing access to local amenities. This combination of convenience and connectivity makes Akabane an appealing location for modern residents.

“Location and everyday convenience continue to play an important role when people choose a rental home in Tokyo,” said a representative familiar with the local residential market. “ROYAL PARKS AKABANE NORTH reflects the growing interest in rental properties that provide residents with access to transportation, essential services, and the wider Tokyo lifestyle.”

For individuals researching ROYAL PARKS AKABANE NORTH Rent, rental conditions may vary depending on factors such as apartment size, layout, floor level, availability, and current market conditions. Prospective tenants should review the latest property information and confirm applicable leasing requirements before making a rental decision.

The ROYAL PARKS AKABANE NORTH Rental Apartments can be considered by a variety of residents, including working professionals, couples, families, and individuals seeking convenient accommodation in Tokyo. Having access to transportation and nearby commercial facilities can help residents manage daily routines while enjoying the wider attractions of the capital.

Akabane also provides an attractive balance between residential convenience and access to central Tokyo. Residents can explore local restaurants, shopping areas, recreational destinations, and community facilities while benefiting from transportation options connecting the neighborhood with other important areas of the city.

As Tokyo’s residential market continues to develop, properties that combine accessibility with practical living environments remain relevant to prospective tenants. ROYAL PARKS AKABANE NORTH represents one option for residents comparing rental apartments according to location, lifestyle requirements, apartment features, and budget.

People interested in ROYAL PARKS AKABANE NORTH Rent are encouraged to check current availability, rental pricing, apartment specifications, contract conditions, and any additional costs with the appropriate property management or leasing representative. Updated information can help prospective residents make a more informed decision when selecting their next home.

With Tokyo continuing to serve as a major center for business, culture, education, and entertainment, demand for well-positioned rental housing is expected to remain an important part of the city’s residential landscape. ROYAL PARKS AKABANE NORTH Rental Apartments offer prospective residents another opportunity to consider modern rental living in the Tokyo metropolitan area.

About ROYAL PARKS AKABANE NORTH

ROYAL PARKS AKABANE NORTH is a residential rental property associated with Tokyo’s diverse housing market. Its location in the Akabane area provides residents with access to local amenities and transportation connections, making it a potential choice for those seeking convenient urban accommodation.

For media inquiries please contact ROYAL PARKS AKABANE NORTH REIT FIN

Email: ueda@rf12.jp 

Media Contact

Organization: ROYAL PARKS AKABANE NORTH REIT FIN

Contact Person: ROYAL PARKS AKABANE NORTH REIT FIN

Website: https://rf12.jp/building/7177/

Email: Send Email

Country:Japan

Release id:48129

The post ROYAL PARKS AKABANE NORTH Highlights Convenient Rental Living in Tokyo appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

RESIDIA TOWER MEGURO FUDOMAE Highlights Convenient Rental Living in Tokyo

Published

2 hours ago

on

August 15, 2026

By

Japan, 15th Aug 2026 — RESIDIA TOWER MEGURO FUDOMAE is attracting attention in Tokyo’s residential rental market as an option for individuals seeking convenient urban accommodation in a well-connected area. The property offers prospective residents an opportunity to enjoy the benefits of Tokyo living while maintaining convenient access to transportation, shopping, dining, and everyday services.

Tokyo remains one of Japan’s leading destinations for professionals, students, families, and people relocating for business and lifestyle opportunities. As demand for conveniently located rental housing continues, RESIDIA TOWER MEGURO FUDOMAE Rentals can be considered by residents looking for a practical home within the Tokyo metropolitan area.

The Meguro and Fudomae area offers a combination of residential surroundings and convenient access to major parts of Tokyo. Residents can benefit from nearby commercial facilities, restaurants, local services, and transportation connections that support everyday commuting and city life.

“Convenience and accessibility are important considerations for people searching for rental housing in Tokyo,” said a representative familiar with the local residential market. “RESIDIA TOWER MEGURO FUDOMAE represents an option for residents who want to combine a comfortable residential environment with access to the wider Tokyo metropolitan area.”

For individuals researching RESIDIA TOWER MEGURO FUDOMAE Rent, rental conditions can differ according to apartment size, layout, floor level, availability, and other property-related factors. Prospective tenants should confirm the latest rental information, applicable fees, and leasing requirements before making a decision.

RESIDIA TOWER MEGURO FUDOMAE Rentals for Modern Urban Lifestyles

RESIDIA TOWER MEGURO FUDOMAE Rentals may appeal to working professionals, couples, individuals, and other residents searching for accommodation with convenient access to Tokyo’s major destinations. The property’s location can make daily travel more manageable while allowing residents to experience the diverse lifestyle opportunities available throughout the city.

The surrounding area provides access to a variety of restaurants, shops, essential services, and recreational opportunities. Residents can enjoy the convenience of urban living while exploring neighborhoods throughout Tokyo for work, leisure, and social activities.

Considering RESIDIA TOWER MEGURO FUDOMAE Rent

People searching for RESIDIA TOWER MEGURO FUDOMAE Rent are encouraged to compare current availability and rental conditions carefully. Important considerations may include monthly rent, apartment specifications, building facilities, initial costs, contract terms, and other conditions established by the relevant leasing or property management representative.

Tokyo’s rental market offers a wide range of residential choices, making it important for prospective tenants to select an apartment that matches their location preferences, lifestyle, and budget. Reviewing updated property information can help residents make a more informed housing decision.

Convenient Access to Tokyo

One of the major considerations when selecting a home in Tokyo is transportation. The Meguro and Fudomae area provides residents with access to transportation options that can support commuting to business districts, educational institutions, shopping areas, and entertainment destinations.

This accessibility can be particularly valuable for professionals and residents who regularly travel between different parts of Tokyo. At the same time, the surrounding neighborhood offers everyday conveniences that can support a comfortable residential routine.

As Tokyo continues to grow as a global center for business, culture, technology, education, and tourism, demand for well-positioned rental properties remains an important part of the city’s housing market. RESIDIA TOWER MEGURO FUDOMAE provides prospective residents with another option to consider when searching for rental accommodation in Tokyo.

About RESIDIA TOWER MEGURO FUDOMAE

RESIDIA TOWER MEGURO FUDOMAE is a residential property associated with Tokyo’s rental housing market. Its location provides access to the wider Meguro and Fudomae area and the transportation, commercial, dining, and lifestyle amenities available throughout the surrounding neighborhood.

For media inquiries please contact RESIDIA TOWER MEGURO FUDOMAE REIT FIND

Email: ueda@rf12.jp 

Media Contact

Organization: RESIDIA TOWER MEGURO FUDOMAE REIT FIND

Contact Person: RESIDIA TOWER MEGURO FUDOMAE REIT FIND

Website: https://rf12.jp/building/77/

Email: Send Email

Country:Japan

Release id:48128

The post RESIDIA TOWER MEGURO FUDOMAE Highlights Convenient Rental Living in Tokyo appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us